共 38 条
[1]
Baker A.L., Thornton L.K., Hides L., Dunlop A., Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials, Curr Pharm Des, 18, pp. 4923-4937, (2012)
[2]
Barrowclough C., Haddock G., Wykes T., Et al., Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial, BMJ, 341, (2010)
[3]
Bechdolf A., Pohlmann B., Guttgemanns J., Geyer C., Lindner K., Ferber C., Gouzoulis-Mayfrank E., Stadienabhängige Motivationsbehandlung bei Patienten mit der Doppeldiagnose Psychose und Sucht: ergebnisse einer randomisierten Studie, Nervenarzt, 83, pp. 888-896, (2012)
[4]
Bennett M.E., Bellack A.S., Gearon J.S., Treating substance abuse in schizophrenia. An initial report, J Subst Abuse Treat, 20, pp. 163-175, (2001)
[5]
Blanchard J.J., Brown S.A., Horan W.P., Sherwood A.R., Substance use disorders in schizophrenia: review, integration, and a proposed model, Clin Psychol Rev, 20, pp. 207-234, (2000)
[6]
Brunette M.F., Dawson R., O'Keefe C.D., Et al., A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia, J Dual Diagn, 7, pp. 50-63, (2011)
[7]
Chambers R.A., Krystal J.H., Self D.W., A neurobiological basis for substance abuse comorbidity in schizophrenia, Biol Psychiatry, 50, pp. 71-83, (2001)
[8]
Cleary M., Hunt G.E., Matheson S.L., Siegfried N., Walter G., Psychosocial interventions for people with both severe mental illness and substance misuse. The Cochrane Collaboration. Editorial Group: Cochrane Schizophrenia Group, John Wiley & Sons Ltd, (2010)
[9]
D'Amelio R., Behrendt B.W.T., Psychoedukation Schizophrenie und Sucht. Manual zur Leitung von Patienten- und Angehörigengruppen, (2007)
[10]
Dixon L., Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes, Schizophr Res, 35, pp. S93-S100, (1999)